Posted by Michael Wonder on 28 Dec 2022
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers
28 December 2022 - Approvals based on significant survival benefits in HIMALAYA, POSEIDON and TOPAZ-1 Phase 3 trials.
AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung.
